Orlando skyline at night, Photo by Bill Dickinson.

The 2017 BMT Tandem Meetings took place February 22-27 in Orlando, Florida.

MRD predicts outcome of HSCT in ALL, study suggests

HSCT preparation
Photo by Chad McNeeley
Minimal residual disease (MRD) measurements before and after hematopoietic stem cell transplant (HSCT) can help predict outcomes in patients with childhood acute lymphoblastic leukemia (ALL), according to researchers. Their work also suggests several other factors can be used to predict event-free survival (EFS) in this patient population,... [Read Article]

Genetic variants linked to HSCT outcomes in ALL

Genome analysis
Image courtesy of the
National Institute of
General Medical Sciences
Results of a genome-wide association study suggest that several genetic variants are associated with outcomes of allogeneic hematopoietic stem cell transplant (HSCT) in patients with acute lymphoblastic leukemia (ALL). Investigators identified several single-nucleotide polymorphisms (SNPs) in ALL patients and their unrelated... [Read Article]

Combo prevents GVHD, prolongs survival in monkeys

Rhesus macaque
Photo by Einar Fredriksen
A 2-drug combination is “an exceptional candidate for clinical translation” as prophylaxis for graft-vs-host disease (GVHD), according to a presenter at the 2017 BMT Tandem Meetings. The combination consists of sirolimus and KY1005, a monoclonal antibody that binds to OX40L and stops it from activating OX40, a... [Read Article]

Study advances precision opioid dosing for mucositis

Child with cancer
Photo by Bill Branson
A pilot study to determine the burden of mucositis in pediatric patients undergoing hematopoietic stem cell transplant (HSCT) found that more than 50% of patients required a change in their opioids either for toxicity or lack of efficacy. Investigators also observed that patients’ genotypes were associated with... [Read Article]

Single dose of ZA pre-transplant prevents bone loss

Bone density scanner <br /> Photo by Steven Fruitsmaak
Bone density scanner
Photo by Steven Fruitsmaak
A single, 4 mg-dose of the bisphosphonate zoledronic acid (ZA) prior to allogeneic hematopoietic stem cell transplant (HSCT) prevents femoral neck (FN) bone loss at day 100 in patients with lymphoid or myeloid malignancies, according to new research.... [Read Article]

VZV vaccine reduces HZ incidence after HSCT

Doctor vaccinating a patient
Photo by Bill Branson
Results of a phase 3 trial suggest an inactivated varicella zoster virus (VZV) vaccine known as V212 can reduce the risk of herpes zoster (HZ) in patients who have undergone autologous hematopoietic stem cell transplant (HSCT). ... [Read Article]

Inpatient palliative care improves QOL for HSCT patients

Doctor and hospitalized patient
Photo courtesy of CDC
New research shows that patients who received inpatient palliative care while undergoing hematopoietic stem cell transplant (HSCT) experienced significant improvements in quality of life (QOL), decreases in depression, and reductions in symptom burden compared to patients who received transplant care alone. ... [Read Article]